With respect to temozolomide response, expression of the repair enzyme MGMT was suggested as the major resistance factor (Gerson, 2002) and lack of MGMT expression in gliomas is mainly based on gene promoter methylation (Silber et al, 1998; Esteller et al, 1999, 2000). The gene discussed is MGMT; the disease is central nervous system cancer.